This company seems to have been delisted
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Athersys
ATHX
A$0.02072
Share price
-33.50%
Change (1 day)
-98.90%
Change (1 year)
Categories
Athersys (ATHX) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : A$67.25 Million
According to Athersys's latest financial reports the company's total liabilities are A$67.25 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Athersys - Total liabilities on balance sheet (from 2005 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | A$75.79 M | 25.42% |
| 2021-12-31 | A$60.43 M | 63.91% |
| 2020-12-31 | A$36.87 M | 40.34% |
| 2019-12-31 | A$26.27 M | -0.56% |
| 2018-12-31 | A$26.42 M | 101.9% |
| 2017-12-31 | A$13.08 M | 19.73% |
| 2016-12-31 | A$10.93 M | 47.32% |
| 2015-12-31 | A$7.41 M | -22.38% |
| 2014-12-31 | A$9.55 M | -40.65% |
| 2013-12-31 | A$16.1 M | 127.54% |
| 2012-12-31 | A$7.07 M | -13.63% |
| 2011-12-31 | A$8.19 M | -17.59% |
| 2010-12-31 | A$9.94 M | -4.71% |
| 2009-12-31 | A$10.43 M | 218.16% |
| 2008-12-31 | A$3.27 M | -37.58% |
| 2007-12-31 | A$5.25 M | 810509.28% |
| 2006-12-31 | A$0 M | |
| 2005-12-31 | N/A | |
| 2004-12-31 | N/A | -100% |
| 2003-12-31 | A$20.92 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | A$127.61 B | 189,663.37% | 🇺🇸 USA |
 Pfizer PFE | A$180.14 B | 267,775.32% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$115.06 B | 170,995.09% | 🇺🇸 USA |
 Moderna
MRNA | A$4.04 B | 5,919.67% | 🇺🇸 USA |
 Johnson & Johnson JNJ | A$177.34 B | 263,601.71% | 🇺🇸 USA |
 United States Lime & Minerals USLM | A$81.4 M | 21.05% | 🇺🇸 USA |
 Merck MRK | A$102.39 B | 152,153.38% | 🇺🇸 USA |
 Sanofi SNY | A$95.42 B | 141,789.88% | 🇫🇷 France |